Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

Prediction of outcome after diagnosis of metachronous contralateral breast cancer

Authors: Sara Alkner, Pär-Ola Bendahl, Mårten Fernö, Jonas Manjer, Lisa Rydén

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

Although 2-20% of breast cancer patients develop a contralateral breast cancer (CBC), prognosis after CBC is still debated. Using a unique patient cohort, we have investigated whether time interval to second breast cancer (BC2) and mode of detection are associated to prognosis.

Methods

Information on patient-, tumour-, treatment-characteristics, and outcome was abstracted from patients' individual charts for all patients diagnosed with metachronous CBC in the Southern Healthcare Region of Sweden from 1977-2007. Distant disease-free survival (DDFS) and risk of distant metastases were primary endpoints.

Results

The cohort included 723 patients with metachronous contralateral breast cancer as primary breast cancer event. Patients with less than three years to BC2 had a significantly impaired DDFS (p = 0.01), and in sub-group analysis, this effect was seen primarily in patients aged <50. By logistic regression analysis, patients diagnosed with BC2 within routine follow-up examinations had a significantly lower risk of developing metastases compared to those who were symptomatic at diagnosis (p < 0.0001). Chemotherapy given after breast BC1 was a negative prognostic factor for DDFS, whereas endocrine treatment and radiotherapy given after BC2 improved DDFS.

Conclusions

In a large cohort of patients with CBC, we found the time interval to BC2 to be a strong prognostic factor for DDFS in young women and mode of detection to be related to risk of distant metastases. Future studies of tumour biology of BC2 in relation to prognostic factors found in the present study can hopefully provide biological explanations to these findings.
Appendix
Available only for authorised users
Literature
1.
Adami HO, Bergstrom R, Hansen J: Age at first primary as a determinant of the incidence of bilateral breast cancer. Cumulative and relative risks in a population-based case-control study. Cancer. 1985, 55 (3): 643-647. 10.1002/1097-0142(19850201)55:3<643::AID-CNCR2820550328>3.0.CO;2-L.CrossRefPubMed
2.
Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar ML, Rotstein S, Perveck L, Ringborg U: Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. Journal of the National Cancer Institute. 1991, 83 (18): 1299-1306. 10.1093/jnci/83.18.1299.CrossRefPubMed
3.
Alkner S, Bendahl PO, Ferno M, Nordenskjold B, Ryden L: Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. Eur J Cancer. 2009, 45 (14): 2496-2502. 10.1016/j.ejca.2009.05.022.CrossRefPubMed
4.
Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, Dickman PW, Hall P: Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol. 2007, 25 (27): 4210-4216. 10.1200/JCO.2006.10.5056.CrossRefPubMed
5.
Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D, Adami HO, Hall P: Genetic implications of bilateral breast cancer: a population based cohort study. The lancet oncology. 2005, 6 (6): 377-382. 10.1016/S1470-2045(05)70174-1.CrossRefPubMed
6.
Brommesson S, Jonsson G, Strand C, Grabau D, Malmstrom P, Ringner M, Ferno M, Hedenfalk I: Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs. BMC clinical pathology. 2008, 8: 6-10.1186/1472-6890-8-6.CrossRefPubMedPubMedCentral
7.
Imyanitov EN, Hanson KP: Molecular pathogenesis of bilateral breast cancer. Cancer letters. 2003, 191 (1): 1-7. 10.1016/S0304-3835(02)00523-2.CrossRefPubMed
8.
Shibata A, Tsai YC, Press MF, Henderson BE, Jones PA, Ross RK: Clonal analysis of bilateral breast cancer. Clin Cancer Res. 1996, 2 (4): 743-748.PubMed
9.
Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S, Rudas M, Gnant M, Jakesz R: Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat. 2001, 67 (1): 1-8. 10.1023/A:1010661514306.CrossRefPubMed
10.
Verkooijen HM, Chatelain V, Fioretta G, Vlastos G, Rapiti E, Sappino AP, Bouchardy C, Chappuis PO: Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat. 2007, 105 (3): 347-357. 10.1007/s10549-006-9455-x.CrossRefPubMed
11.
Heron DE, Komarnicky LT, Hyslop T, Schwartz GF, Mansfield CM: Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer. 2000, 88 (12): 2739-2750. 10.1002/1097-0142(20000615)88:12<2739::AID-CNCR12>3.0.CO;2-J.CrossRefPubMed
12.
Takahashi H, Watanabe K, Takahashi M, Taguchi K, Sasaki F, Todo S: The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. Breast cancer (Tokyo, Japan). 2005, 12 (3): 196-202.CrossRef
13.
Dawson LA, Chow E, Goss PE: Evolving perspectives in contralateral breast cancer. Eur J Cancer. 1998, 34 (13): 2000-2009. 10.1016/S0959-8049(98)00208-1.CrossRefPubMed
14.
Burns PE, Dabbs K, May C, Lees AW, Birkett LR, Jenkins HJ, Hanson J: Bilateral breast cancer in northern Alberta: risk factors and survival patterns. Canadian Medical Association journal. 1984, 130 (7): 881-886.PubMedPubMedCentral
15.
Quan G, Pommier SJ, Pommier RF: Incidence and outcomes of contralateral breast cancers. American journal of surgery. 2008, 195 (5): 645-650. 10.1016/j.amjsurg.2008.01.007. discussion 650CrossRefPubMed
16.
Kuo WH, Yen AM, Lee PH, Chen KM, Wang J, Chang KJ, Chen TH, Tsau HS: Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. British journal of cancer. 2009, 100 (4): 563-570. 10.1038/sj.bjc.6604898.CrossRefPubMedPubMedCentral
17.
Holmberg L, Adami HO, Ekbom A, Bergstrom R, Sandstrom A, Lindgren A: Prognosis in bilateral breast cancer. Effects of time interval between first and second primary tumours. British journal of cancer. 1988, 58 (2): 191-194. 10.1038/bjc.1988.191.CrossRefPubMedPubMedCentral
18.
Carmichael AR, Bendall S, Lockerbie L, Prescott R, Bates T: The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol. 2002, 28 (4): 388-391. 10.1053/ejso.2002.1266.CrossRefPubMed
19.
Lu W, Schaapveld M, Jansen L, Bagherzadegan E, Sahinovic MM, Baas PC, Hanssen LM, van der Mijle HC, Brandenburg JD, Wiggers T, De Bock GH: The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer. Eur J Cancer. 2009, 45 (17): 3000-3007. 10.1016/j.ejca.2009.08.007.CrossRefPubMed
20.
Rubino C, Arriagada R, Delaloge S, Le MG: Relation of risk of contralateral breast cancer to the interval since the first primary tumour. British journal of cancer. 2010, 102 (1): 213-9. 10.1038/sj.bjc.6605434.CrossRefPubMed
21.
Imyanitov EN, Suspitsin EN, Grigoriev MY, Togo AV, Kuligina E, Belogubova EV, Pozharisski KM, Turkevich EA, Rodriquez C, Cornelisse CJ, Hanson KP, Theillet C: Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. International journal of cancer. 2002, 100 (5): 557-564. 10.1002/ijc.10530.CrossRefPubMed
22.
Hemminki K, Granstrom C: Morphological types of breast cancer in family members and multiple primary tumours: is morphology genetically determined?. Breast Cancer Res. 2002, 4 (4): R7-10.1186/bcr444.CrossRefPubMedPubMedCentral
23.
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005, 365 (9453): 60-62. 10.1016/S0140-6736(04)17666-6.CrossRefPubMed
24.
Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. Journal of the National Cancer Institute. 1996, 88 (21): 1529-1542. 10.1093/jnci/88.21.1529.CrossRefPubMed
25.
Systemic treatment of early breast cancer by hormonal cytotoxic or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992, 339 (8785): 71-85.
26.
Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, Paik S, Wolmark N: Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. Journal of the National Cancer Institute. 2004, 96 (7): 516-523. 10.1093/jnci/djh097.CrossRefPubMed
27.
Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK: Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol. 2005, 23 (21): 4687-4694. 10.1200/JCO.2005.04.076.CrossRefPubMed
28.
Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P: Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003, 361 (9354): 296-300. 10.1016/S0140-6736(03)12342-2.CrossRefPubMed
29.
Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators. JAMA. 1994, 271 (20): 1587-1592. 10.1001/jama.271.20.1587.
30.
Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V: Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994, 271 (20): 1593-1597. 10.1001/jama.271.20.1593.CrossRefPubMed
31.
Lu WL, Jansen L, Post WJ, Bonnema J, Van de Velde JC, De Bock GH: Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat. 2009, 114 (3): 403-412. 10.1007/s10549-008-0023-4.CrossRefPubMed
32.
Houssami N, Ciatto S, Martinelli F, Bonardi R, Duffy SW: Early detection of second breast cancers improves prognosis in breast cancer survivors. Ann Oncol. 2009, 20 (9): 1505-1510. 10.1093/annonc/mdp037.CrossRefPubMed
33.
Jacobs HJ, van Dijck JA, de Kleijn EM, Kiemeney LA, Verbeek AL: Routine follow-up examinations in breast cancer patients have minimal impact on life expectancy: a simulation study. Ann Oncol. 2001, 12 (8): 1107-1113. 10.1023/A:1011624829512.CrossRefPubMed
34.
Grunfeld E, Noorani H, McGahan L, Paszat L, Coyle D, van Walraven C, Joyce J, Sawka C: Surveillance mammography after treatment of primary breast cancer: a systematic review. Breast (Edinburgh, Scotland). 2002, 11 (3): 228-235.CrossRef
35.
de Bock GH, Bonnema J, van der Hage J, Kievit J, van de Velde CJ: Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. J Clin Oncol. 2004, 22 (19): 4010-4018. 10.1200/JCO.2004.06.080.CrossRefPubMed
36.
Lawrence G, Wallis M, Allgood P, Nagtegaal ID, Warwick J, Cafferty FH, Houssami N, Kearins O, Tappenden N, O'Sullivan E, Duffy SW: Population estimates of survival in women with screen-detected and symptomatic breast cancer taking account of lead time and length bias. Breast Cancer Res Treat. 2009, 116 (1): 179-185. 10.1007/s10549-008-0100-8.CrossRefPubMed
37.
Duffy SW, Nagtegaal ID, Wallis M, Cafferty FH, Houssami N, Warwick J, Allgood PC, Kearins O, Tappenden N, O'Sullivan E, Lawrence G: Correcting for lead time and length bias in estimating the effect of screen detection on cancer survival. American journal of epidemiology. 2008, 168 (1): 98-104. 10.1093/aje/kwn120.CrossRefPubMed
38.
Paci E, Coviello E, Miccinesi G, Puliti D, Cortesi L, De Lisi V, Ferretti S, Mangone L, Perlangeli V, Ponti A, Ravaioli A, de' Bianchi PS, Segnan N, Stracci F, Tumino R, Zarcone M, Zorzi M, Zappa M, IMPACT Working Group: Evaluation of service mammography screening impact in Italy. The contribution of hazard analysis. Eur J Cancer. 2008, 44 (6): 858-865. 10.1016/j.ejca.2008.02.026.CrossRefPubMed
39.
Dawson SJ, Duffy SW, Blows FM, Driver KE, Provenzano E, LeQuesne J, Greenberg DC, Pharoah P, Caldas C, Wishart GC: Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. British journal of cancer. 2009, 101 (8): 1338-1344. 10.1038/sj.bjc.6605317.CrossRefPubMedPubMedCentral
40.
Joensuu H, Lehtimaki T, Holli K, Elomaa L, Turpeenniemi-Hujanen T, Kataja V, Anttila A, Lundin M, Isola J, Lundin J: Risk for distant recurrence of breast cancer detected by mammography screening or other methods. Jama. 2004, 292 (9): 1064-1073. 10.1001/jama.292.9.1064.CrossRefPubMed
41.
Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA: Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. Journal of the National Cancer Institute. 2005, 97 (16): 1195-1203. 10.1093/jnci/dji239.CrossRefPubMed
42.
Wishart GC, Greenberg DC, Britton PD, Chou P, Brown CH, Purushotham AD, Duffy SW: Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone?. British journal of cancer. 2008, 98 (11): 1741-1744. 10.1038/sj.bjc.6604368.CrossRefPubMedPubMedCentral
Metadata
Title
Prediction of outcome after diagnosis of metachronous contralateral breast cancer
Authors
Sara Alkner
Pär-Ola Bendahl
Mårten Fernö
Jonas Manjer
Lisa Rydén
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-114

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Research article

Validation of prognostic scores for survival in cancer patients beyond first-line therapy

Research article

Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study

Research article

Genetic polymorphisms of DNA double strand break gene Ku70 and gastric cancer in Taiwan

Research article

The strengths and limitations of routine staging before treatment with abdominal CT in colorectal cancer

Research article

Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation

Research article

Support vector machine model for diagnosis of lymph node metastasis in gastric cancer with multidetector computed tomography: a preliminary study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits